Regulus Therapeutics Inc. (NASDAQ:RGLS – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $10.80.
A number of research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a report on Friday, August 9th. Canaccord Genuity Group upped their price target on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a report on Friday, September 6th. Finally, Oppenheimer reiterated an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a report on Wednesday, August 14th.
Get Our Latest Stock Analysis on Regulus Therapeutics
Institutional Investors Weigh In On Regulus Therapeutics
Regulus Therapeutics Stock Performance
RGLS opened at $1.61 on Monday. The business has a 50 day moving average price of $1.65 and a 200 day moving average price of $2.04. Regulus Therapeutics has a twelve month low of $1.08 and a twelve month high of $3.79.
Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). On average, research analysts expect that Regulus Therapeutics will post -0.8 earnings per share for the current fiscal year.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
Recommended Stories
- Five stocks we like better than Regulus Therapeutics
- Health Care Stocks Explained: Why You Might Want to Invest
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- What Are Dividend Champions? How to Invest in the Champions
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- What is the S&P/TSX Index?
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.